AMGEN INC — Director's Dealing 2024

May 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2024-05-07

Reporting Person: Bradner James E. (EVP, R&D, & Chief Sci. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-07	Common Stock	A	2863	—	Acquired	25438	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-07	Nqso (Right to Buy)	$300.30	A	18603	Acquired	2034-05-07	Common Stock (18603)	Direct

Footnotes

F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028,
respectively.

F2: These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028; and 2,863 RSUs which will vest in installments of 944 on 5/7/2026, 945 on 5/7/2027, and 974 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 182 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting
person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

F4: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.